by In2Pharma | Oct 13, 2025 | News
The Netherlands Requests for the withdrawal of marketing authorizations and parallel import licenses for human medicines effective 31 December 2025 — the so-called “end-of-year withdrawals” — must be received by the Medicines Evaluation Board (CBG) no later than 1...
by In2Pharma | Feb 28, 2019 | News
European Union In light of the withdrawal of the United Kingdom from the European Union, the European Commission has published a letter on the rules for batch testing of medicinal products after the Brexit. The competent authorities may allow marketing authorisation...
by In2Pharma | Dec 18, 2018 | News
EMA Following a review of disabling and potential long-term side effects of fluoroquinolone and quinolone antibiotics, the Pharmacovigilance Risk Assessment Committee (PRAC) has recommended a restriction of the use of these products. It concerns fluoroquinolone and...
